Purpose: Privacy-protecting analytic and data-sharing methods that minimize the disclosure risk of sensitive information are increasingly important due to the growing interest in utilizing data across multiple sources. We conducted a simulation study to examine how avoiding sharing individual-level data in a distributed data network can affect analytic results.
| INTRODUCTION
Distributed data networks such as the National Patient-Centered Clinical Research Network (PCORnet) 1 and the Sentinel System 2 are becoming a platform of choice for more rapid generation of real-world evidence. Multi-database analysis typically requires data be shared across sites and combined centrally at a coordinating center.
Traditionally, detailed data including individual-level characteristics such as demographics and medical history was shared. However, this need for sharing potentially identifiable information across data partners can hinder multi-database research due to data partners' concerns about patient privacy, data security, and inappropriate or unauthorized use of data. 3, 4 There have been efforts to create data-sharing platforms or technical infrastructure that offer better patient privacy protection. [5] [6] [7] [8] Multiple analytic and data-sharing methods have also been proposed to address these concerns. 9 Rassen et al compared privacy-protecting methods including propensity score (PS)-based methods and full covariate sharing in two empirical examples-the association of proton pump inhibitors and myocardial infarction, 10 and the association of biological antirheumatic drugs and myocardial infarction. 11 They found similar results from full covariate sharing and individual-level PS sharing. In the setting of survival analysis,
an alternative approach to sharing individual-level data is to request risk-set information. Each risk set forms a single dataset record consisting of counts of individuals experiencing the study outcome at each relevant time point during follow-up and individuals remaining at risk at that time point. 12 Toh et al examined several methods, including pooled individual-level data analysis, risk-set data analysis, and meta-analysis, 12 in empirical examples of the association between bariatric surgery and re-hospitalization 3 and the association between anti-hypertensives and angioedema. 13 The latter study 13 included a simulation substudy limited to a setting without confounding.
To our knowledge, these more privacy-protecting methods have not been directly compared in robust simulation, and their relative performance remains poorly understood. This motivated us to conduct the current study to assess the relative performance of various approaches to estimating a conditional hazard ratio (HR) in time-to-event data in a simulated distributed data network.
Specifically, we aimed to examine how different data-sharing methods in combination with several confounding adjustment methods affect analytic performance across various simulation scenarios compared with sharing individual-level data.
| METHODS
We compared the performance of various data-sharing methods on estimation of HRs conditional on data partners (details and examples in eAppendix Section 1), using results from pooled individual-level analysis as the reference.
| Data generation
We generated seven independent covariates in the base scenario. The first covariate was a standard normal variable. The other variables were binary Bernoulli variables with prevalence varying from 5% to 50%. We generated treatment assignment probability from a main terms logistic regression model. Variable was given varying levels of influence by assigning different coefficients-the odds ratio of treatment ranged from 0.3 to 3.0. Survival outcome assignment used the exponential model. We varied the incidence of the outcome (0.01%, 0.1%, 1%, and 5% annual incidence), prevalence of the treatment (5%, 10%, 25%, and 50%), size of sites (500, 1000, 5000, 10 000, and 20 000), number of sites (2,4,8 and 16) , treatment effect (HR 0.8, 1.0, and 1.2), and variability of covariate distribution across sites (none, small, moderate, and large) to generate a range of simulation scenarios (eAppendix Section 2).
| Confounder summary score estimation
We used PS 14 and disease risk score (DRS) 15 as the confounder summary score. PS was estimated within each site by regressing the treatment variable on all covariates. DRS was estimated among the untreated individuals within each site although in practice estimation using historical data is increasingly recommended. 16 Both models were correctly specified. eAppendix (Section 3) provides more details.
| Confounding control using summary scores
We performed one-to-one PS and DRS matching of untreated to treated subjects using nearest neighbor method with a caliper 17 set to 20% of the sample standard deviation. 18 PS matching was on the logit scale, and DRS was matched on the log relative hazard scale.
Stratification was based on deciles of the scores in the entire cohort.
Weights were constructed as the inverse probability of treatment weights (IPTW) 19, 20 and matching weights (MW). 21, 22 See Table 1 for classification and eAppendix Section 4 for more detailed description of the estimands.
| Data reduction, sharing, and analysis
We compared analyses of individual-level data pooled across all participating sites with analyses of three types of summarized data requested from sites: risk-set data, summary-table data, or effectestimate data with variances (eAppendix Sections 5 and 6).
Individual-level data contained the outcome, exposure, and one of the following: match set indicators, stratum indicators, or weights.
The risk-set data contained risk set composition at each unique event time within the matched cohort or each stratum. In the case of weighting, the risk sets also carried information on the total weights and the variance of weights. The summary- • Overall, we obtained valid results with aggregate-level data-sharing approaches in many settings.
• Care must be taken with the effect-estimate data (metaanalysis) approach in infrequent exposure and rare outcome scenarios.
• Our simulation software is available at https://github. com/kaz-yos/distributed/.
stratum. The effect-estimate data contained the site-specific point estimate of treatment effect and its variance. With a matched design, these data outputs were generated using site-specific Cox regression. Stratified Cox regression (allowing for stratum-specific baseline hazard function) was used in the within-site stratified analysis. The within-site weighted analyses were performed using weighted Cox regression with the robust sandwich variance estimator. 23 We aggregated data into one combined dataset for the final analysis. Final data analysis differed based on the data-sharing methods but was always stratified by site (eAppendix Section 6). This mimicked the process and analysis typically conducted in an actual distributed data network, where stratification by site may mitigate potential differences in important characteristics, such as baseline outcome rate, across the participating sites.
| Performance assessment
The average of point estimates was used for two types of comparisons.
The first comparison was against the underlying true estimand in the data generation process, which gave the bias, ie, average deviation from the truth. The second comparison was against the pooled individuallevel data analysis, which we called agreement for distinction.
Two types of precision measures were obtained: the simulationbased standard error (SE; standard deviation of point estimates across iterations) and average estimated SE. We took the former as the true variability of the estimator. The average estimated SE was then compared with the simulation-based SE to examine accuracy.
We examined the proportion of simulation iterations that failed to produce interpretable results. A low proportion indicated that the method failed less often, although it might not necessarily mean more accurate results. We give the precise definitions of these assessment metrics in eAppendix Section 7.
3 | RESULTS Matching and both PS weighting methods were less biased than stratification on summary score decile.
| Base scenario
The ratios of average SEs to the corresponding simulation SE (eFigure 1) were on average within ±5% of 1.0 for all methods, indicating accurate estimation of variability. We did not observe substantial difference across data-sharing methods within each adjustment method. PS IPTW sometimes produced some outliers, including those overestimating by 25% (confidence interval would be too wide)
although it was less extreme when combined with the meta-analysis method.
FIGURE 1 Distribution of log hazard ratio point estimates by confounding adjustment method (panels) and data-sharing method (X axis) in the base scenario. The true underlying log HR was 0 (HR In the subsequent sections, we summarize findings from our analyses for each performance metric.
| Bias and agreement
Across three true conditional HRs (1. Heterogeneity of covariate distributions across sites had little impact on bias (eFigure 2) (<0.01 on log HR scale). Agreement with the pooled individual-level data analysis was good, except for PS IPTW, which exhibited minor disagreement.
| True and estimated variability of point estimates
The precision of estimates generally improved as exposure prevalence increased (eFigure 3). The accuracy of SE estimates was similar across Across all methods, the precision of HR estimates improved as outcome incidence increased (eFigure 5). Varying the incidence of outcome produced different degrees of accuracy of the SE estimates, most noticeably in PS matching and DRS methods (eFigure 6). In PS matching, lowering the outcome incidence led to overestimation of the SEs, in particular for meta-analyses. The SEs for DRS matching and stratification were underestimated at the incidence of 0.1%, but became more accurate at 0.01%. Importantly, this result at the incidence of 0.01% was not accompanied by improvement in bias ( Figure 3 ).
When we varied the site size and number of sites, the underlying true variability were similar across data-sharing methods and decreased with increasing site size or number of sites (eFigure 7).
The SE estimates demonstrated similar trends when reducing incidence at small site sizes of 500 and 1000 (eFigure 8).
Varying the covariate distributions across sites had little impact on the simulation SE (eFigure 9). SE estimates were on average accurate and none of the methods underestimated by greater than 5% (eFigure 10). 
| Proportions of successful simulation iterations

| DISCUSSION
We examined various privacy-protecting analytic and data-sharing methods through a simulation study to assess whether restricting data sharing could affect the performance of analytic methods compared Small but noticeable differences were observed in extreme settings such as rare outcome (0.01%), infrequent exposure (5%), and small sites (500 or 1000 patients). Aggregating and sharing event counts and person-time data into a summary-level table worked well in this constant-hazard setting with low incidence. Risk-set data analysis was shown to be a useful intermediary between summary-table sharing and individual-level data sharing. The extension of risk-set data analysis to PS-weighted data produced results on bias and precision of HR estimates comparable to pooled individual-level data analysis, although the SE estimates showed a minor difference when used with PS IPTW in infrequent exposure settings.
Data-sharing methods had little impact on bias and precision of log HR estimates within each confounding adjustment method in most simulated scenarios with exposure prevalence >10%, outcome incidence >0.1%, and each site contributing >10 000 patients. This implies that in the setting where each data partner provides a sufficient sample of similar patient populations, a meta-analysis of site-specific effect estimates, the data-sharing method with the least amount of data sharing, may be an attractive option. The additional benefit of this approach is that the investigator at the coordinating center will always see the site-specific effect estimates, which may help identify treatment effect heterogeneity.
In the presence of treatment effect heterogeneity across sites, the issue about the appropriateness of pooling data from all sites applies to all data-sharing methods studied. When there is treatment effect heterogeneity, presenting site-specific results separately along with respective baseline patient characteristics may be a better option than Our study complements the existing literature in several ways. A previous review 9 provides an overview of confounding adjustment and outcome analysis in distributed data networks. In this paper, we systematically classified various distributed analytic and data-sharing methods using three different domains-the type of summary scores, confounding adjustment methods, and data-sharing methods (Table 1) . We considered PS and DRS, two of the most commonly used confounder summary scores in the context of matching, stratification, and weighting. Data-sharing methods, the last axis of classification, was the main interest of the current study. This classification is by no means comprehensive. It nevertheless clarifies how these three axes are orthogonal and can be combined.
We implemented an experimental method for risk-set data combined with PS weighting. This method produced point estimates comparable to the corresponding pooled individual-level data-sharing method. SE estimates were also similar in most scenarios. However, in the scenario with very different treatment arm sizes (≤ 10% treated), the IPTW SE estimates were further from the actual variability than individual-level data analysis (eFigure 2) although MW was less affected. Additional assessment of this promising approach is warranted.
To our knowledge, the current study is the most extensive examination of different data-sharing methods in combination with various commonly used confounding adjustment techniques. We introduced some restrictions to the data generation mechanisms to make the comparison of the methods tractable. The number of covariates was small, and they were independent. High-dimensional and collinear covariates may require special handling, such as penalized regression 25 for PS and DRS modeling. We made the true underlying treatment effect of interest homogeneous across data partners to emulate a setting in which data pooling across sites is appropriate. In practice, theoretical and empirical evidence of homogeneity of treatment effects across sites should determine the appropriateness of combining data from different sites. The survival outcome was generated with a constant hazard of events over time. Poisson regression using summary-table data sharing that reduces the full time-to-event data into totals of event counts and person-time for the treated and untreated is comparable to Cox regression if the underlying hazards are time-constant. 26 When the underlying hazards are time-varying, for example, higher adverse event rates are expected early after medication initiation, summary-table data may require stratification into clinically meaningful time periods. In this case, one may prefer sharing fully time-stratified risk-set data. We applied IPTW without truncation or trimming. This may have resulted in sensitivity to covariate non-overlap and instability compared with MW. We did not examine methods that include PS or DRS as independent variables in outcome regression models because they require other data-sharing techniques that are beyond the scope of our study (eg, distributed regression). 3 To conclude, data-sharing methods had little impact on bias and precision of log HR estimates in most simulated scenarios. Small differences were observed in extreme settings such as rare outcome, infrequent exposure, and small sites. In practice, meta-analysis of site-specific effect estimates is useful if treatment effect heterogeneity across sites is minimal. In the presence of substantial heterogeneity, investigation of treatment effect modification can be done by sharing site-specific estimates within levels of potential effect modifiers or covariate-stratified risk-set data.
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